<DOC>
	<DOCNO>NCT01833741</DOCNO>
	<brief_summary>This study evaluate bimatoprost 0.01 % ( LUMIGAN® RC ) patient elevate intraocular pressure ( IOP ) due primary open angle glaucoma ( POAG ) ocular hypertension ( OHT ) clinical setting .</brief_summary>
	<brief_title>A Study LUMIGAN® RC Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Elevated IOP due either primary openangle glaucoma ocular hypertension Determined treat physician require treatment LUMIGAN® RC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>